367 related articles for article (PubMed ID: 34890492)
1. The variants of SARS-CoV-2 and the challenges of vaccines.
Han X; Ye Q
J Med Virol; 2022 Apr; 94(4):1366-1372. PubMed ID: 34890492
[TBL] [Abstract][Full Text] [Related]
2. COVID-19 vaccine breakthrough infections.
Gupta RK; Topol EJ
Science; 2021 Dec; 374(6575):1561-1562. PubMed ID: 34941414
[TBL] [Abstract][Full Text] [Related]
3. SARS-CoV-2 evolution and vaccines: cause for concern?
Williams TC; Burgers WA
Lancet Respir Med; 2021 Apr; 9(4):333-335. PubMed ID: 33524316
[No Abstract] [Full Text] [Related]
4. SARS-CoV-2 Infection: New Molecular, Phylogenetic, and Pathogenetic Insights. Efficacy of Current Vaccines and the Potential Risk of Variants.
Rotondo JC; Martini F; Maritati M; Mazziotta C; Di Mauro G; Lanzillotti C; Barp N; Gallerani A; Tognon M; Contini C
Viruses; 2021 Aug; 13(9):. PubMed ID: 34578269
[TBL] [Abstract][Full Text] [Related]
5. Will Mutations in the Spike Protein of SARS-CoV-2 Lead to the Failure of COVID-19 Vaccines?
Jia Z; Gong W
J Korean Med Sci; 2021 May; 36(18):e124. PubMed ID: 33975397
[TBL] [Abstract][Full Text] [Related]
6. Seroresponse to SARS-CoV-2 Vaccines among Maintenance Dialysis Patients over 6 Months.
Hsu CM; Weiner DE; Manley HJ; Aweh GN; Ladik V; Frament J; Miskulin D; Argyropoulos C; Abreo K; Chin A; Gladish R; Salman L; Johnson D; Lacson EK
Clin J Am Soc Nephrol; 2022 Mar; 17(3):403-413. PubMed ID: 35144972
[TBL] [Abstract][Full Text] [Related]
7. COVID-19 Variants and Vaccine Development.
Zhao Z; Bashiri S; Ziora ZM; Toth I; Skwarczynski M
Viruses; 2024 May; 16(5):. PubMed ID: 38793638
[TBL] [Abstract][Full Text] [Related]
8. Haplotype distribution of SARS-CoV-2 variants in low and high vaccination rate countries during ongoing global COVID-19 pandemic in early 2021.
Bui NN; Lin YT; Huang SH; Lin CW
Infect Genet Evol; 2022 Jan; 97():105164. PubMed ID: 34848355
[TBL] [Abstract][Full Text] [Related]
9. Elicitation of Broadly Neutralizing Antibodies against B.1.1.7, B.1.351, and B.1.617.1 SARS-CoV-2 Variants by Three Prototype Strain-Derived Recombinant Protein Vaccines.
Yang Y; Zang J; Xu S; Zhang X; Yuan S; Wang H; Lavillette D; Zhang C; Huang Z
Viruses; 2021 Jul; 13(8):. PubMed ID: 34452287
[TBL] [Abstract][Full Text] [Related]
10. Predicted Epitope Abundance Supports Vaccine-Induced Cytotoxic Protection Against SARS-CoV-2 Variants of Concern.
Martín-Galiano AJ; Díez-Fuertes F; McConnell MJ; López D
Front Immunol; 2021; 12():732693. PubMed ID: 34899692
[TBL] [Abstract][Full Text] [Related]
11. Serum neutralising activity against SARS-CoV-2 variants elicited by CoronaVac.
Chen Y; Shen H; Huang R; Tong X; Wu C
Lancet Infect Dis; 2021 Aug; 21(8):1071-1072. PubMed ID: 34051887
[No Abstract] [Full Text] [Related]
12. Immunogenicity of SCB-2019 Coronavirus Disease 2019 Vaccine Compared With 4 Approved Vaccines.
Ambrosino D; Han HH; Hu B; Liang J; Clemens R; Johnson M; Siber G; Goldblatt D
J Infect Dis; 2022 Jan; 225(2):327-331. PubMed ID: 34888662
[TBL] [Abstract][Full Text] [Related]
13. Nucleic acid delivery of immune-focused SARS-CoV-2 nanoparticles drives rapid and potent immunogenicity capable of single-dose protection.
Konrath KM; Liaw K; Wu Y; Zhu X; Walker SN; Xu Z; Schultheis K; Chokkalingam N; Chawla H; Du J; Tursi NJ; Moore A; Adolf-Bryfogle J; Purwar M; Reuschel EL; Frase D; Sullivan M; Fry B; Maricic I; Andrade VM; Iffland C; Crispin M; Broderick KE; Humeau LMPF; Patel A; Smith TRF; Pallesen J; Weiner DB; Kulp DW
Cell Rep; 2022 Feb; 38(5):110318. PubMed ID: 35090597
[TBL] [Abstract][Full Text] [Related]
14. Combining spike- and nucleocapsid-based vaccines improves distal control of SARS-CoV-2.
Dangi T; Class J; Palacio N; Richner JM; Penaloza MacMaster P
Cell Rep; 2021 Sep; 36(10):109664. PubMed ID: 34450033
[TBL] [Abstract][Full Text] [Related]
15. Evolution, Mode of Transmission, and Mutational Landscape of Newly Emerging SARS-CoV-2 Variants.
Chakraborty C; Sharma AR; Bhattacharya M; Agoramoorthy G; Lee SS
mBio; 2021 Aug; 12(4):e0114021. PubMed ID: 34465019
[TBL] [Abstract][Full Text] [Related]
16. Novel coronavirus mutations: Vaccine development and challenges.
Luo WR; Wu XM; Wang W; Yu JL; Chen QQ; Zhou X; Huang X; Pan HF; Liu ZR; Gao Y; He J
Microb Pathog; 2022 Dec; 173(Pt A):105828. PubMed ID: 36243381
[TBL] [Abstract][Full Text] [Related]
17. SARS-CoV-2 Vaccines Based on the Spike Glycoprotein and Implications of New Viral Variants.
Martínez-Flores D; Zepeda-Cervantes J; Cruz-Reséndiz A; Aguirre-Sampieri S; Sampieri A; Vaca L
Front Immunol; 2021; 12():701501. PubMed ID: 34322129
[TBL] [Abstract][Full Text] [Related]
18. A Review of the Progress and Challenges of Developing a Vaccine for COVID-19.
Sharma O; Sultan AA; Ding H; Triggle CR
Front Immunol; 2020; 11():585354. PubMed ID: 33163000
[TBL] [Abstract][Full Text] [Related]
19. Sieve analysis to understand how SARS-CoV-2 diversity can impact vaccine protection.
Rolland M; Gilbert PB
PLoS Pathog; 2021 Mar; 17(3):e1009406. PubMed ID: 33765086
[No Abstract] [Full Text] [Related]
20. Safety, mucosal and systemic immunopotency of an aerosolized adenovirus-vectored vaccine against SARS-CoV-2 in rhesus macaques.
Xu F; Wu S; Yi L; Peng S; Wang F; Si W; Hou L; Zhu T
Emerg Microbes Infect; 2022 Dec; 11(1):438-441. PubMed ID: 35094672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
